J
Jean-Jacques Grob
Researcher at Aix-Marseille University
Publications - 369
Citations - 58038
Jean-Jacques Grob is an academic researcher from Aix-Marseille University. The author has contributed to research in topics: Medicine & Melanoma. The author has an hindex of 71, co-authored 310 publications receiving 45788 citations. Previous affiliations of Jean-Jacques Grob include University of Sydney.
Papers
More filters
Journal ArticleDOI
Treatment of Recurrent Melanoma Following Adjuvant Therapy
N. Malissen,Jean-Jacques Grob +1 more
Journal ArticleDOI
Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in checkmate 067.
F. Stephen Hodi,Vanna Chiarion-Sileni,Rene Gonzalez,Jean-Jacques Grob,Piotr Rutkowski,Christopher D. Lao,C. Lance Cowey,Dirk Schadendorf,John Wagstaff,Reinhard Dummer,Paola Queirolo,Michael Smylie,Mark S. Butler,Andrew G. Hill,Ivan Marquez-Rodas,Corey Ritchings,Leon A. Sakkal,Peter Feng Wang,Jedd D. Wolchok,James Larkin +19 more
TL;DR: In this article , NIVO + IPI has demonstrated durable clinical benefit at 7.5 y in pts with advanced melanoma in the phase 3 CheckMate 067 study, suggesting that being alive and progression-free for ≥ 3 y (PFS ≥ 3y) may be a good surrogate for longterm clinical benefit.
Journal ArticleDOI
858P Automated detection of melanoma: Comparing a convolutional neural network (CNN) approach with an algorithm assessing disorder in the pattern of pigmented lesions, intended to mimick onco-dermatologists' visual analysis
J. Monnier,A.C. Gouabou Foahom,M. Serdi,J. Collenne,Rabah Iguernaissi,C. Gaudy-Marqueste,Jean-Luc Damoiseaux,Jean-Jacques Grob,Djamal Merad +8 more
TL;DR: In this paper , the authors used entropy, skewness, standard deviation, and kurtosis features to characterize melanoma disorder in dermoscopic images of 1533 melanomas and 6124 nevi.
Journal ArticleDOI
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401.
Reinhard Dummer,Pippa Corrie,Ralf Gutzmer,Tarek Meniawy,M. Del Vecchio,Céleste Lebbé,M. Guidal,Caroline Dutriaux,Brigitte Dréno,Nicolas Meyer,Pier Francesco Ferrucci,Stéphane Dalle,Muhammad A. Khattak,Jean-Jacques Grob,Karen Briscoe,James Larkin,Sandrine Mansard,Thierry Lesimple,Massimo Guidoboni,Erika Richtig,Rudolf Herbst,Maurice Lobo,Margarita Askelson,Paolo A. Ascierto,Michele Maio +24 more
TL;DR: The CheckMate 401 study as discussed by the authors evaluated the safety and efficacy of nivolumab plus ipilimumab (i.e., 1 mg/kg plus 3mg/kg) followed by nivlumab monotherapy in clinically diverse patient populations with advanced melanoma.